The optimize project: beyond first-line therapy in metastatic renal cell carcinoma

被引：0
|
作者：
Daniel Castellano
Joaquim Bellmunt
机构：
[1] University Hospital 12 de Octubre,Medical Oncology Department
[2] Hospital Universitario del Mar-IMIM,undefined
来源：
Cancer and Metastasis Reviews | 2012年 / 31卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1 / 2
页数：1
相关论文
共 50 条
  • [21] New TKI/IO Combinations in the First-line Therapy of metastatic Renal Cell Carcinoma Comment
    Grabbert, Markus
    [J]. AKTUELLE UROLOGIE, 2022, 53 (01) : 18 - +
  • [22] First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology
    Numakura, Kazuyuki
    Kobayashi, Mizuki
    Muto, Yumina
    Sekine, Yuya
    Takahashi, Makoto
    Kashima, Soki
    Yamamoto, Ryohei
    Koizumi, Atsushi
    Nara, Taketoshi
    Saito, Mitsuru
    Narita, Shintaro
    Nanjyo, Hiroshi
    Habuchi, Tomonori
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [23] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Hutson, Thomas E.
    Gallardo, Jorge
    Lesovoy, Vladmir
    Al-Shukri, Salman
    Stus, Viktor
    Bair, A. H.
    Rosbrook, Brad
    Bycott, Paul W.
    Tarazi, Jamal Christo
    Kim, Sinil
    Vogelzang, Nicholas J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [24] Non-interventional study of first-line therapy in advanced or metastatic renal cell carcinoma
    Rexer, Heidrun
    Wunderlich, Heiko
    Doehn, Christian
    [J]. AKTUELLE UROLOGIE, 2024, 55 (03)
  • [25] First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology
    Kazuyuki Numakura
    Mizuki Kobayashi
    Yumina Muto
    Yuya Sekine
    Makoto Takahashi
    Soki Kashima
    Ryohei Yamamoto
    Atsushi Koizumi
    Taketoshi Nara
    Mitsuru Saito
    Shintaro Narita
    Hiroshi Nanjyo
    Tomonori Habuchi
    [J]. Scientific Reports, 10
  • [26] Erectile function in patients with metastatic renal cell carcinoma treated with first-line therapy.
    Tsimafeyeu, Ilya
    Zukov, Ruslan
    Borisov, Pavel S.
    Leonenko, Valentina
    Kuznetsov, Vladimir
    Bondarenko, Anastasia
    Tishova, Yulia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 383 - 383
  • [27] COST EFFECTIVENESS OF SUNITINIB AS FIRST-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA IN CHINA
    Shi, Q.
    Yin, H.
    Xuan, J.
    Wu, Y.
    Cheng, G.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A638 - A638
  • [28] Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis
    Cattrini, Carlo
    Messina, Carlo
    Airoldi, Chiara
    Buti, Sebastiano
    Roviello, Giandomenico
    Mennitto, Alessia
    Caffo, Orazio
    Gennari, Alessandra
    Bersanelli, Melissa
    [J]. THERAPEUTIC ADVANCES IN UROLOGY, 2021, 13
  • [29] Axitinib with or without dose titration as first-line therapy for metastatic renal cell carcinoma (mRCC)
    Jonasch, E.
    Bair, A.
    Chen, Y.
    Rini, B. I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Metastatic renal cell carcinoma: which treatments in first-line setting?
    Mery, Benoite
    Jones, Samuel
    Vallard, Alexis
    Rowinski, Elise
    Guillot, Aline
    Magne, Nicolas
    [J]. BULLETIN DU CANCER, 2018, 105 : S235 - S241
12345